HK1052181A1 - 作為雙重組胺h1和h3激動劑或拮抗劑的取代咪唑 - Google Patents

作為雙重組胺h1和h3激動劑或拮抗劑的取代咪唑

Info

Publication number
HK1052181A1
HK1052181A1 HK03104438.9A HK03104438A HK1052181A1 HK 1052181 A1 HK1052181 A1 HK 1052181A1 HK 03104438 A HK03104438 A HK 03104438A HK 1052181 A1 HK1052181 A1 HK 1052181A1
Authority
HK
Hong Kong
Prior art keywords
agonists
antagonists
substituted imidazoles
dual histamine
histamine
Prior art date
Application number
HK03104438.9A
Other languages
English (en)
Inventor
G Aslanian Robert
B Rosenblum Stuart
Wa Mutahi Mwangi
Shih Neng-Yang
J Piwinski John
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Corp filed Critical Schering Corp
Publication of HK1052181A1 publication Critical patent/HK1052181A1/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/64—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms, e.g. histidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Obesity (AREA)
  • Cardiology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Anesthesiology (AREA)
  • Immunology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
HK03104438.9A 2000-09-20 2003-06-20 作為雙重組胺h1和h3激動劑或拮抗劑的取代咪唑 HK1052181A1 (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US23404000P 2000-09-20 2000-09-20
PCT/US2001/029064 WO2002024658A2 (en) 2000-09-20 2001-09-18 Substituted imidazoles as dual histamine h1 and h3 agonists or antagonists

Publications (1)

Publication Number Publication Date
HK1052181A1 true HK1052181A1 (zh) 2003-09-05

Family

ID=22879630

Family Applications (1)

Application Number Title Priority Date Filing Date
HK03104438.9A HK1052181A1 (zh) 2000-09-20 2003-06-20 作為雙重組胺h1和h3激動劑或拮抗劑的取代咪唑

Country Status (14)

Country Link
US (1) US6518287B2 (zh)
EP (1) EP1318983B1 (zh)
JP (1) JP2004509870A (zh)
CN (1) CN1461299A (zh)
AR (1) AR032895A1 (zh)
AT (1) ATE411983T1 (zh)
AU (1) AU2001292723A1 (zh)
CA (1) CA2421823A1 (zh)
DE (1) DE60136284D1 (zh)
ES (1) ES2313985T3 (zh)
HK (1) HK1052181A1 (zh)
MX (1) MXPA03002447A (zh)
MY (1) MY129677A (zh)
WO (1) WO2002024658A2 (zh)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050090527A1 (en) * 2003-01-28 2005-04-28 Schering Corporation Combination of H1, H3 and H4 receptor antagonists for treatment of allergic and non-allergic pulmonary inflammation, congestion and allergic rhinitis
BRPI0514857A (pt) 2004-09-03 2008-05-06 Celgene Corp composto ou um sal, solvato ou hidrato farmaceuticamente aceitável do mesmo, composição farmacêutica, e, métodos para inibir a angiogênese, para inibir ou reduzir a polimerização da tubulina ou a estabilidade da tubulina em uma célula, para inibir a atividade de pde4 em uma célula, para inibir atividade do fator-alfa de necrose de tumor (tnf-alfa) em uma célula, para tratar ou melhorar um distúrbio inflamatório, para tratar ou melhorar cáncer, para inibir a proliferação de célula cancerosa, para marcar, bloquear ou destruir a função de vasculatura tumoral, para marcar, bloquear ou destruir o endotélio de vasos tumor, para marcar, bloquear ou destruir a função de vasculatura tumoral e inibir a angiogênese em um tumor e para tratar ou melhorar um distúrbio do sistema nervoso central
US20100222393A1 (en) * 2005-12-30 2010-09-02 Naresh Kumar Muscarinic receptor antagonists
JP5498168B2 (ja) * 2006-12-01 2014-05-21 ブリストル−マイヤーズ スクイブ カンパニー アテローム性動脈硬化および循環器疾患の治療のためのｃｅｔｐ阻害剤としてのｎ−（（３−ベンジル）−２，２−（ビス−フェニル）−プロパン−１−アミン誘導体
WO2013151982A1 (en) 2012-04-03 2013-10-10 Arena Pharmaceuticals, Inc. Methods and compounds useful in treating pruritus, and methods for identifying such compounds

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3512084A1 (de) * 1985-04-02 1986-10-09 Ludwig Heumann & Co GmbH, 8500 Nürnberg Guanidinderivate, verfahren zu ihrer herstellung und diese verbindungen enthaltende arzneimittel
FR2586562B1 (fr) 1985-09-02 1989-03-10 Inst Nat Sante Rech Med Composition pharmaceutique contenant de l'a-methylhistamine
DE3631334A1 (de) * 1986-09-15 1988-03-17 Heumann Pharma Gmbh & Co Neue imidazolylguanidinderivate, verfahren zu ihrer herstellung und diese verbindungen enthaltende arzneimittel
GB8916947D0 (en) 1989-07-25 1989-09-13 Smith Kline French Lab Medicaments
ATE109979T1 (de) * 1990-03-30 1994-09-15 Heumann Pharma Gmbh & Co Verwendung von guanidinderivaten zur herstellung eines arzneimittels mit npy-antagonistischer wirkung.
GB9115740D0 (en) 1991-07-20 1991-09-04 Smithkline Beecham Plc Medicaments
WO1993012093A1 (en) 1991-12-18 1993-06-24 Schering Corporation Imidazolyl-alkyl-piperazine and -diazepine derivatives as histamine h3 agonists/antagonists
FR2686084B1 (fr) 1992-01-10 1995-12-22 Bioprojet Soc Civ Nouveaux derives de l'imidazole, leur preparation et leurs applications therapeutiques.
US5352707A (en) 1992-03-26 1994-10-04 Harbor Branch Oceanographic Institution, Inc. Method for treating airway congestion
ATE234290T1 (de) 1993-11-15 2003-03-15 Schering Corp Phenylalkyl-imidazole als h3-rezeptor- antagonisten
FR2732017B1 (fr) 1995-03-21 2000-09-22 Inst Nat Sante Rech Med Nouveaux derives de l'imidazole antagonistes et/ou agonistes du recepteur h3 de l'histamine, leur preparation et leurs applications therapeutiques
ATE214604T1 (de) 1997-06-24 2002-04-15 Novo Nordisk As Verwendung von somatostatin agonisten und antagonisten zur behandlung von augenkrankheiten
US5869479A (en) 1997-08-14 1999-02-09 Schering Corporation Treatment of upper airway allergic responses
US6211182B1 (en) * 1999-03-08 2001-04-03 Schering Corporation Imidazole compounds substituted with a six or seven membered heterocyclic ring containing two nitrogen atoms

Also Published As

Publication number Publication date
US20020103235A1 (en) 2002-08-01
AU2001292723A1 (en) 2002-04-02
CA2421823A1 (en) 2002-03-28
CN1461299A (zh) 2003-12-10
ES2313985T3 (es) 2009-03-16
WO2002024658A2 (en) 2002-03-28
US6518287B2 (en) 2003-02-11
MXPA03002447A (es) 2003-07-21
JP2004509870A (ja) 2004-04-02
ATE411983T1 (de) 2008-11-15
DE60136284D1 (de) 2008-12-04
EP1318983B1 (en) 2008-10-22
WO2002024658A3 (en) 2002-07-11
EP1318983A2 (en) 2003-06-18
AR032895A1 (es) 2003-12-03
MY129677A (en) 2007-04-30

Similar Documents

Publication Publication Date Title
EP1206262A4 (en) Y NEUROPEPTID ANTAGONISTS: SPIROISOQUINOLINONE DERIVATIVES
PL366233A1 (en) Substituted pyridoindoles as serotonin agonists and antagonists
ZA200107917B (en) Bicyclic heteroaromatic compounds useful as LH agonists.
IL150632A0 (en) Corticotropin releasing factor antagonists
PL376477A1 (en) Substituted piperazines, (1,4) diaszepines, and 2,5-diazabicyclo (2.2.1) heptanes as histamine h1 and/or h3 antagonists or histamine h3 reverse antagonists
IL154604A0 (en) Guanidinobenzamides as mc4-r agonists
PL359619A1 (en) Glucagon antagonists/inverse agonists
PL372295A1 (en) Quinoline derivatives as npy antagonists
MXPA03006484A (es) Derivados de imidazolilo como inhibidores del factor de liberacion de corticotropina.
AU2002223501A1 (en) Glucagon antagonists/inverse agonists
AU2002223500A1 (en) Glucagon antagonists/inverse agonists
HUP0401756A3 (en) Substituted benzimidazole compounds and their use
GB0015562D0 (en) Heterocycles
HK1052182B (zh) 作為雙重組胺h1和h3激動劑或拮抗劑的取代咪唑
HK1052179A1 (zh) 作為雙重組胺h1和h3激動劑或拮抗劑的取代咪唑
EP0986553A4 (en) DIHYDROPYRIMIDONE DERIVATIVES AS NPY ANTAGONISTS
HK1052180A1 (zh) 作為雙重組胺h1和h3激動劑或拮抗劑的取代咪唑
HK1052181A1 (zh) 作為雙重組胺h1和h3激動劑或拮抗劑的取代咪唑
AU7635401A (en) Hetaryl-substituted heterocycles
SI1261588T1 (en) IMIDAZOLE COMPOUNDS AS Alpha2-ADRENOCEPTORS ANTAGONISTS
GB0101223D0 (en) Histamine receptor antagonists
EP1202738A4 (en) DIHYDROPYRAZINE DERIVATIVES AS NPY ANTAGONISTS
AU6043500A (en) New npy antagonists
GB9927761D0 (en) Anti-microbial compounds and feed additives incorporating the same
GB0009125D0 (en) Antagonists